ESR1 and neoplasm: In this study, we developed tamoxifen (TR), palbociclib (PR), and tamoxifen + palbociclib (TPR) resistant variants from T47D and MCF-7 ER + breast cancer cell lines to elucidate the mechanisms involved in tumor resistance and explore novel potential targets.